This trade-off has largely disappeared.
For a generation, the pursuit of parenthood through IVF carried a hidden cost: the higher the hope, the greater the risk of twins and the complications that follow. A large Australian study presented at the European Society of Human Reproduction and Embryology's 2026 annual meeting suggests that medicine has quietly resolved this dilemma — not through a single dramatic discovery, but through the patient accumulation of laboratory refinements that now yield a 68% live birth rate while reducing multiple pregnancies to under 3%. It is a reminder that progress in medicine often arrives not as revelation, but as the slow, compounding discipline of doing many small things better.
- The old arithmetic of IVF — transfer more embryos, accept more risk — has been quietly dismantled by a decade of incremental laboratory advances.
- A study of nearly 18,400 women across seven Australian clinics found that 95% of transfers now involve a single embryo, yet live birth rates have climbed well above historical benchmarks.
- Multiple birth rates, once exceeding 20% and carrying serious medical dangers for mothers and infants, have fallen to just 2.9% — a shift that reframes what 'success' in fertility treatment means.
- Age remains the stubborn variable: women under 35 reach an 84.5% cumulative success rate, while those aged 41–42 see that figure fall to 30.1%, tracking the biological reality of egg quality decline.
- The findings challenge the routine use of preimplantation genetic testing, suggesting that optimized lab practice alone — not additional screening — is sufficient for most patients to achieve strong, safe outcomes.
For decades, fertility medicine operated on an uncomfortable trade-off: transfer two embryos to improve the odds of pregnancy, and accept the elevated risks of twins — prematurity, complications, cesarean delivery — as the price of success. New research suggests that calculation no longer holds.
Presented at the 42nd Annual Meeting of the European Society of Human Reproduction and Embryology, the study tracked 18,396 women across seven Australian fertility clinics between 2012 and 2023. It found a 68.2% cumulative live birth rate over three treatment cycles — substantially higher than the historical range of 53 to 59 percent — while using single embryo transfer in 95.3% of cases and holding the multiple birth rate to just 2.9%, down from rates that once exceeded 20%.
The improvement traces to a convergence of laboratory refinements rather than any single breakthrough. Blastocyst culture — allowing embryos to develop to day five or six before transfer — shifted from exception to standard practice. Embryo vitrification dramatically improved survival after freezing. Together, these advances made freeze-all strategies viable, enabling clinics to transfer embryos one at a time across cycles without sacrificing success rates. Lead researcher Dr. Dean Morbeck described blastocyst culture as the foundational change, one that cascaded into better incubators, lower oxygen conditions, and less disruption to developing embryos.
Success remains age-dependent: women under 35 achieved an 84.5% cumulative live birth rate, falling to 74.4% for those aged 35–37, 57.7% for ages 38–40, and 30.1% for women aged 41–42. Yet even older age groups showed marked improvement over historical data. The study also found that most live births occurred without preimplantation genetic testing, suggesting routine screening is unnecessary for many patients — though it retains value for older women and those with recurrent pregnancy loss.
The broader implication is that conservative, evidence-based practice — optimizing the laboratory, following guidelines, transferring one embryo at a time — can steadily improve outcomes while reducing risk. For patients navigating the emotional and financial weight of fertility treatment, the story of modern IVF is one of quiet, cumulative progress.
For decades, fertility clinics faced an uncomfortable arithmetic: transfer two embryos to improve the odds of pregnancy, and you'd likely end up with twins. The trade-off seemed unavoidable. A woman desperate for a child would accept the medical risks of a multiple pregnancy—the higher rates of prematurity, complications, cesarean delivery—as the price of success.
That calculation has shifted. New research presented at the 42nd Annual Meeting of the European Society of Human Reproduction and Embryology shows that modern IVF can now deliver strong pregnancy outcomes while keeping multiple births rare. Researchers tracking 18,396 women across seven Australian fertility clinics between 2012 and 2023 found a 68.2% cumulative live birth rate over three treatment cycles, achieved while using single embryo transfer in 95.3% of cases and maintaining a multiple birth rate of just 2.9%.
The improvement is substantial when set against the historical record. Before the widespread adoption of contemporary laboratory techniques, clinics reported three-cycle live birth rates in the 53 to 59 percent range, often paired with multiple pregnancy rates exceeding 20 percent. The gap reflects a decade of incremental refinement: blastocyst culture—allowing embryos to develop to day five or six before transfer—has become standard rather than exceptional. Embryo vitrification, a rapid-freezing technique, dramatically improved survival rates after thawing. Freeze-all strategies, where embryos are transferred one at a time in later cycles rather than during the initial hormone stimulation, became viable. Each advance built on the others.
Dr. Dean Morbeck, the study's lead author, emphasized that the shift in laboratory practice was foundational. "The biggest change has been that blastocyst culture moved from being an exception to becoming the default," he said. That single change drove improvements across clinics—better incubators, reduced oxygen conditions, less disruption to developing embryos. When combined with vitrification, which made frozen embryo transfers nearly as effective as fresh ones, it enabled the freeze-all approach. The result: clinics could transfer embryos one by one without sacrificing success rates.
Success, however, remains age-dependent. Women under 35 achieved an 84.5% cumulative live birth rate over three cycles. That fell to 74.4% for women aged 35 to 37, 57.7% for those 38 to 40, and 30.1% for women 41 to 42. The pattern reflects biological reality—egg quality declines with age—but even in older age groups, outcomes improved markedly compared to historical data.
The study also tracked changes over time. Between 2012 and 2015, 48.3% of fertilized eggs developed into usable blastocysts; by 2017 to 2021, that rose to 57.6%. Single embryo transfer increased from 92.8% to 97.3% over the same period, while the multiple birth rate fell from 3.2% to 2.7%. The data challenged a long-standing assumption: that transferring multiple embryos was necessary to maximize success. "For many years, transferring two embryos increased the chance of pregnancy from any one transfer, but often came with twin pregnancy rates approaching 30%," Morbeck explained. "What our data show is that this trade-off has largely disappeared."
The findings also suggest that routine genetic testing of embryos—preimplantation genetic testing for aneuploidy, or PGT-A—is not necessary for all patients. The study included 25% of women who underwent PGT-A in one or more cycles, yet most live births occurred without it. Morbeck noted that genetic testing remains valuable for women of advanced maternal age and those with recurrent pregnancy loss, but the data reassure many patients that strong outcomes are achievable without routine screening. The implication is clear: evidence-based, conservative approaches—optimizing laboratory practice, adhering to guidelines, transferring single embryos—can progressively increase live birth rates while reducing the medical risks that come with multiple pregnancies. For patients seeking a safe and cost-effective path to parenthood, the future of IVF appears to be one of steady, cumulative improvement rather than dramatic breakthrough.
Notable Quotes
The biggest shift has been that blastocyst culture has moved from being an exception to becoming the default.— Dr. Dean Morbeck, lead author
A concerted effort to reduce twin pregnancies has not cost patients their chance of taking home a baby—it has coincided with that chance increasing.— Dr. Dean Morbeck
The Hearth Conversation Another angle on the story
Why does it matter that they moved from transferring two embryos to one? Wasn't that just a numbers game?
It was a safety game dressed up as a numbers game. Transferring two embryos did increase the chance of pregnancy from that single transfer—that part was true. But it also meant roughly 30% of pregnancies were twins, which carries real medical risk: prematurity, low birth weight, complications for the mother. The old logic was that you needed that trade-off. What this study shows is you don't anymore.
How did they break the trade-off?
Better embryo culture—letting them develop to day five or six instead of day three—meant they could identify which embryos were actually viable. Then vitrification, the freezing technique, got so good that frozen embryos worked nearly as well as fresh ones. So instead of transferring two embryos in one cycle and hoping, they could transfer one, freeze the others, and come back later if needed. Same success rate, much lower risk of twins.
The age numbers are striking. 84.5% for women under 35, but 30.1% for women 41 to 42. That's a huge drop.
That's biology. Egg quality declines with age—it's not something the clinic can engineer around. But even at 30%, that's still better than what older women had before. The point isn't that age doesn't matter. It's that modern technique has lifted outcomes across the board.
They mention that most live births happened without genetic testing. Why would clinics have been doing routine genetic testing if it wasn't necessary?
Partly because it was available and seemed like it should help. Partly because older women, who have higher rates of chromosomal abnormalities, might benefit from it. But the data suggest you don't need to screen every embryo from every patient. It's a cost and a delay. For many people, the old-fashioned approach—good culture, single transfer, patience—works just fine.
What's the real significance here?
It's that incremental, unglamorous work—better incubators, refined protocols, one small improvement after another—can add up to something that genuinely changes outcomes. No breakthrough drug, no genetic miracle. Just steady refinement of what you're already doing.